Based on various roles played by the Hippo pathway and its downstream effectors YAP and TAZ in breast cancer, it seems that modulating the activity of the Hippo pathway holds a hope of being therapeutic target in breast cancer. The gene discussed is YAP1; the disease is breast carcinoma.